NVAX - ノババックス (Novavax Inc.) ノババックス

 NVAXのチャート


 NVAXの企業情報

symbol NVAx
会社名 Novavax Inc. (ノババックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ノババックス(Novavax Inc.)は臨床段階のバイオ医薬品会社である。同社は組換えナノ粒子ワクチン及びアジュバントの発見・開発・商業化に焦点を当てる。同社は組換えワクチンセグメントの開発を通じて事業を行っている。同社は、組換えナノ粒子ワクチン技術を用いて、既知疾患及び新興疾患に対応するワクチン候補物質を製造する。同社の製品パイプラインは、呼吸器合胞体ウイルス(RSV)、季節性インフルエンザ、パンデミックインフルエンザおよびエボラウイルス(EBOV)の臨床開発におけるワクチン候補の感染症に焦点を当てる。同社の人用鉛アジュバントであるMatrix-Mは、パンデミックインフルエンザH7N9ワクチン候補のフェーズI / II臨床試験にある。また、第I相臨床試験でEBOVワクチン候補と併せてMatrix-Mを試験している。同社は中東呼吸器症候群(MERS)を含む感染性疾患で、前臨床段階の追加プログラムを開発している。   ノババックスは、臨床段階の米国バイオ医薬品企業。組換えナノ粒子ワクチンおよび抗原性補強剤の発見、開発、商業化に従事する。呼吸器合胞体ウイルス、季節性インフルエンザと新型インフルエンザのための臨床開発などの感染症に対象を当て遺伝子組み換えによるワクチンを開発する。   Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
本社所在地 20 Firstfield Road Garthersburg MD 20878 USA
代表者氏名 James Francis Young ジェームズ・フランシス・ヤング
代表者役職名 Independent Chairman of the Board
電話番号 +1 240-268-2000
設立年月日 1987年
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 347人
url www.novavax.com
nasdaq_url https://www.nasdaq.com/symbol/nvax
adr_tso
EBITDA EBITDA(百万ドル) -165.13200
終値(lastsale) 2.065
時価総額(marketcap) 790052064.935
時価総額 時価総額(百万ドル) 723.09850
売上高 売上高(百万ドル) 39.19000
企業価値(EV) 企業価値(EV)(百万ドル) 874.46250
当期純利益 当期純利益(百万ドル) -186.29300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Novavax Inc. revenues increased 65% to $20.4M. Net loss increased 3% to $90.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 16% to $83.5M (expense) Labor_Related Expenses in R&D increase of 18% to $5.6M (expense).

 NVAXのテクニカル分析


 NVAXのニュース

   Is Novavax (NVAX) Outperforming Other Medical Stocks This Year?  2020/03/02 16:30:11 Zacks Investment Research
Is (NVAX) Outperforming Other Medical Stocks This Year?
   Thinking about buying stock in Canopy Growth Corp, General Motors, 3M, Novavax, or Vir Biotechnology?  2020/02/28 14:31:00 PR Newswire
NEW YORK, Feb. 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGC, GM, MMM, NVAX, and VIR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   The S&P 500 pulls off its quickest correction since the Great Depression  2020/02/28 14:21:32 Business Insider
The S&P 500 slipped into a correction after its 4.4% drop on Thursday, the dourest warning yet of the coronavirus' drag on US stocks. The six consecutive days of drops mark the benchmark index's quickest correction since 1933, when the S&P 500 plummeted 13.3% in two days, according to The Financial Times. A correction is defined as a 10% drop from a record high. The index's massive drop arrived as new virus deaths outside of China ratcheted up concerns that the outbreak would escalate to an economically crippling pandemic. Monitor the S&P 500 live here . The S&P 500 slipped through the week to post its fastest correction since the Great Depression as fears of a coronavirus-driven recession tore into markets around the world. The key index notched its biggest single-day drop since 2011 on Thursday after plunging 4.4%. The S&P 500 index wiped out its year-to-date gains after its Monday and Tuesday slumps and now sits 9% below where it closed December 31. The index's rapid downturn has also pushed the S&P 500 to 12% below its February 19 high.
   Top Analyst Upgrades and Downgrades: Beyond Meat, CBOE, Chesapeake Energy, Dollar General, FLIR, Gilead, Lyft, Novavax, RBS, Uber, Zoom and More  2020/02/28 14:00:35 24/7 Wall street
   A small group of scientists, execs, and VCs are $277 million richer as their companies race to create a coronavirus vaccine. Here are 7 who have raked in huge sums.  2020/02/28 13:24:17 Business Insider
Gilead , Moderna , and Novavax have all enjoyed massive gains after announcing potential coronavirus drugs, leading their executives, scientists, and early investors to rake in millions. The profits come as global markets tank on growing coronavirus concerns. Moderna has gained the most of the three since Friday's close, jumping 60% after announcing on Monday it submitted the first coronavirus vaccine for human trials. Here are the seven shareholders to collectively profit $277 million from the surging biotech stocks. Visit the Business Insider homepage for more stories. Three biotech stocks are surging on the possibility of coronavirus drugs and minting millions of dollars for their biggest shareholders. Gilead , Moderna , and Novavax have all outperformed the falling stock market in recent days as the three drug developers rush to introduce preventative vaccines and treatments. The coronavirus has caused more than 2,800 deaths and infected more than 82,000 since breaking out in Wuhan, China.
   'Contagion' is now one of the most popular movies on iTunes because of the Wuhan coronavirus outbreak. Here's how it compares to reality.  2020/01/31 00:42:00 Business Insider
A coronavirus outbreak that originated in Wuhan, China, has killed at least 200 people and infected more than 9,700 since December. In the weeks since public-health officials reported the first coronavirus case, many people have searched for and watched the 2011 movie "Contagion." The film depicts a fictional worldwide pandemic that spreads from animals to people in Hong Kong, then kills tens of millions worldwide. Here's how the pandemic from the movie "Contagion" differs from the current Wuhan coronavirus outbreak. Visit Business Insider's homepage for more stories . The 2011 film "Contagion" opens to the sound of a woman coughing. The universal sound of sickness, her cough is heavy and full of mucous. It comes from Beth Emhoff, played by Gwyneth Paltrow, who is patient zero in a pandemic that kills at least 26 million people worldwide in less than a month. The fictional pandemic in "Contagion," called MEV-1 in the movie, is a hybrid of influenza and the deadly Nipah virus that emerged in Malaysia in the late 1990s.
   Has Novavax (NVAX) Outpaced Other Medical Stocks This Year?  2020/01/29 16:30:09 Zacks Investment Research
Is (NVAX) Outperforming Other Medical Stocks This Year?
   Novavax soars as company works on China virus vaccine  2020/01/27 19:12:14 Yahoo Finance
As fears continue to grow over the spread of the coronavirus, companies like Novavax are working to create a vaccine. Yahoo Finance’s Anjalee Khemlani joins Zack Guzman, Brian Cheung and Radio Show Host Ben Kissel on YFi PM to to break down what biotech stocks to watch.
   3 Biotech Stocks Are Soaring Because Everyone Wants a Coronavirus Vaccine  2020/01/27 17:47:00 Barron's
Biotech companies Moderna, Novavax, and Inovio Pharmaceuticals are working on vaccines for the Wuhan coronavirus. Their stocks soared as worries over the spread of the illness weigh on broader markets.
   These 3 small pharmaceutical stocks are surging after announcing work on a coronavirus vaccine (INO, MRNA, NVAX)  2020/01/27 17:36:06 Business Insider
Shares of Inovio Pharmaceuticals, Moderna Inc., and Novavax Inc. all surged Monday as China's coronavirus spread further. On Thursday, the Coalition for Epidemic Preparedness Innovations announced that it will provide as much as $11 million in funding to the three companies to develop new vaccines against the Wuhan strain . Here's how much each company gained. Read more on Business Insider. Amid a rout that's sending global stocks and oil prices lower, three pharmaceutical companies are seeing outsized gains because of China's coronavirus outbreak. Shares of Inovio Pharmaceuticals, Moderna Inc., and Novavax Inc. all surged Monday as China's coronavirus spread further. The companies continued rallies sparked on Thursday, when the Coalition for Epidemic Preparedness Innovations, a public-private nonprofit based in Norway, announced that it will provide as much as $11 million in funding to the three companies to develop new vaccines against the Wuhan strain . In addition to the three pharmaceutical companies, the University of Queensland in Australia is also working on a vaccine for the coronavirus and received funding from the CEPI .
   Better Buy: Novavax vs. Inovio Pharmaceuticals | The Motley Fool  2019/11/26 14:59:12 The Motley Fool
These two pharma micro-caps are approaching climactic phase 3 trials.
   The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate  2019/11/22 13:18:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) (raised full-year guidance following completion of Otezla purchase from Celgene) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cue Biopharma Inc (NASDAQ: CUE ) Epizyme Inc (NASDAQ: EPZM ) Kamada Ltd. (NASDAQ: KMDA ) Kodiak Sciences Inc (NASDAQ: KOD ) Molecular Templates Inc (NASDAQ: MTEM ) Recro Pharma Inc (NASDAQ: REPH ) (completed spin-off of Baudax Bio in a bid to a become a pure play CDMO) Down In The Dumps (Biotech stocks that hit 52-week lows on Nov. 21.) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) (received European approval for its Rhokiinsa 0.02% for the reduction of elevated intraocular pressure) Affimed NV (NASDAQ: AFMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) CareDx Inc (NASDAQ: CDNA ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Genprex Inc (NASDAQ: GNPX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Interpace Biosciences Inc (NASDAQ: IDXG ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its previously announced common stock offering) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) MacroGenics Inc (NASDAQ: MGNX ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) Neon Therapeutics Inc (NASDAQ: NTGN ) (announced a changed focus and the elimination of 24% of workforce) Novavax, Inc. (NASDAQ: NVAX ) Nuvectra Corp (NASDAQ: NVTR ) Onconova Therapeutics …
   Why 2020 could be a make-or-break year for Novavax  2019/11/08 20:04:38 Yahoo Finance
A new year will bring phase 3 trial results for Novavax's flu vaccine — and the company's got a lot riding on them.
   One Thing To Remember About The Novavax, Inc. (NASDAQ:NVAX) Share Price  2019/11/08 18:36:04 Yahoo Finance
If you're interested in Novavax, Inc. (NASDAQ:NVAX), then you might want to consider its beta (a measure of share…
   Will Novavax (NVAX) Report Negative Q3 Earnings? What You Should Know  2019/10/30 14:33:33 Zacks Investment Research
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ノババックス NVAX Novavax Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)